Single Pharmaceutical-Based Strategy Aims to Solve Neurological and Psychiatric Disorders
(firmenpresse) - LOS ANGELES, CA -- (Marketwire) -- 10/19/11 -- One pharmaceutical company, Cortex Pharmaceuticals (OTCBB: CORX) is now engaged in a tireless quest to treat a wide variety of ailments that range in symptoms and complexity from Parkinson's Disease and Fragile X syndrome to ADHD and obstructive sleep apnea.
An exclusive Q&A with Mark Varney, President and CEO of Cortex Pharmaceuticals, reveals details about research by Cortex and its collaborators, including how Professors Gary Lynch and Christine Gall from the University of California, Irvine, have demonstrated that certain compounds may restore function to previously damaged areas of the brain.
The exclusive report is now available at:
In addition, investors may access BioMedReports' for use as a tool in more profitable trading by visiting:
News developments and live healthcare sector updates are available constantly via twitter at:
About BioMedReports.Com
BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com
Media Contacts Only:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail:
Tel: +1 323 472 4480
Fax: +1 888 210 3556
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.10.2011 - 05:36 Uhr
Sprache: Deutsch
News-ID 1047432
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LOS ANGELES, CA
Phone:
Kategorie:
Investment Opinion
Anmerkungen:
Diese Pressemitteilung wurde bisher 133 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Single Pharmaceutical-Based Strategy Aims to Solve Neurological and Psychiatric Disorders
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
